The First Clinical Study Shows a Key NAD+ Intermediate NMN Safe for Human Use
February 25, 2020
Keio University School of Medicine
A research team at Keio University has shown for the first time that nicotinamide mononucleotide (NMN), a promising compound for anti-aging intervention, can be safely administered to healthy humans. The Keio University research team was led by Prof. Hiroshi Itoh of the Department of Internal Medicine (Endocrinology, Metabolism, and Nephrology,), Prof. Kazuo Tsubota of the Department of Ophthalmology, Prof. Masato Yasui of the Department of Pharmacology, and Prof. Hideyuki Okano of the Department of Physiology, and the study was conducted in collaboration with Prof. Shin-ichiro Imai of Washington University School of Medicine in St. Louis.
Recent studies in animal models have shown that the administration of NMN increases the amount of nicotinamide adenine dinucleotide (NAD+) in various organs and improves age-associated functional decline and disease conditions. However, the safety of NMN in humans have remained unclear.
Since 2016, the research team has conducted a clinical trial study to investigate the safety of single administration of NMN in ten healthy men and has confirmed that it can be safely administered and that it is effectively metabolized in the body. This study is expected to inform future treatment of age-associated diseases.
The results of this research were published in Endocrine Journal on November 2, 2019.
For further information, please refer to the following PDF file.